Full-Time

Director – HCP Marketing Lead

T1D

Confirmed live in the last 24 hours

Vertex Pharmaceuticals

Vertex Pharmaceuticals

1,001-5,000 employees

Develops medicines for serious diseases

Compensation Overview

$195.2k - $292.8k/yr

+ Bonus + Equity Awards

Expert

Company Does Not Provide H1B Sponsorship

Boston, MA, USA

Hybrid-Eligible role allows for remote work up to two days per week.

Category
General Marketing
PR & Communications
Growth & Marketing
Required Skills
Word/Pages/Docs
Data Analysis
Excel/Numbers/Sheets
Requirements
  • Direct experience with communications review committee for review of tactics
  • Ability to oversee generation of insights and apply those insights to business problems/opportunities and make strategic recommendations
  • Analytical mindset, with demonstrated ability to lead others to solve complex problems
  • Demonstrated ability to develop strategy, make strategic recommendations, and monitor performance
  • An entrepreneurial and innovative spirit, with an ability to develop creative solutions to complex problems
  • Advanced knowledge of market forecasts and relationship of business drivers to revenue
  • Advanced working knowledge of MS Office applications, including PPT, Excel and Word
  • Experience in pharmaceutical marketing or closely related field(s) (e.g., pharmaceutical sales, ad agency, etc.)
Responsibilities
  • Leverages primary and secondary research to develop clear, actionable insights that accurately inform the key drivers and barriers of adoption for cell therapy
  • Works cross functionally to ensure an integrated launch strategy that includes market access, field leadership, medical affairs, and communications
  • Ensures that the brand strategy is translated with an effective tactical plan for HCPs, treatment centers, and care teams
  • Refines how the potential treatment model will work, and develop a robust plan to ensure the stakeholder experience is seamless from referral through treatment
  • Leads data and tech efforts to support cell therapy adoption including CRM software and marketing automation tools, working closely with our data and tech teams
  • Measures the impact of our initiatives based on ROI and agilely pivot our investments to maximize impact, constantly looking for opportunities for automation and efficiency
  • Engages with the HCP and treatment center thought-leader community to understand challenges and opportunities, gleam critical insights, and influence perceptions for cell therapy
  • Collaborates with internal Legal, Medical, and Regulatory partners to deliver a compelling, effective brand campaign for the target HCPs and related care teams
  • Works with external agencies to execute promotional strategy and tactics through personal and non-personal channels, while ensuring external partners remain on-time and on-budget
  • Collaborates with field leadership and team members to obtain input on launch strategies and tactics; ensures relevant launch KPIs are established, monitored, and optimized
  • Leads a team to deliver tactics against the multiple audiences described above
  • Role models and instills a culture of compliance focused on ethics and integrity in all we do
Vertex Pharmaceuticals

Vertex Pharmaceuticals

View

Vertex Pharmaceuticals develops medicines for serious diseases, focusing on conditions like cystic fibrosis. The company conducts extensive research and development to create new drugs, often collaborating with other biotech firms to enhance its therapeutic offerings. One of its notable products is ivacaftor, which has shown effectiveness in treating cystic fibrosis. Vertex differentiates itself from competitors through its commitment to scientific innovation and strategic partnerships that expand its research capabilities. The goal of Vertex Pharmaceuticals is to improve the quality of life for patients with severe and life-threatening conditions by bringing effective treatments to market.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

1989

Simplify Jobs

Simplify's Take

What believers are saying

  • Vertex's EU approval expands its cystic fibrosis treatment market.
  • Partnerships with Arbor and Orna enhance Vertex's gene therapy capabilities.
  • Increased rare disease research funding supports Vertex's R&D efforts.

What critics are saying

  • Competition in cystic fibrosis treatments threatens Vertex's market share.
  • High R&D costs and trial delays could strain Vertex's finances.
  • Regulatory challenges may limit Vertex's drug market expansion.

What makes Vertex Pharmaceuticals unique

  • Vertex focuses on transformative medicines for serious diseases, like cystic fibrosis.
  • The company invests heavily in R&D and strategic biotech partnerships.
  • Vertex's innovative cell and gene therapies set it apart in the biotech industry.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Company News

BioSpace
Apr 14th, 2025
Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis

Vertex researcher, Paul Negulescu Ph.D., receives the 2025 Canada Gairdner International Award for pioneering Research and discovery of medicines for Cystic Fibrosis.

Biz Owner Daily
Apr 7th, 2025
EU Approves Expanded Label for Vertex Pharmaceuticals' Cystic Fibrosis Treatment

Vertex Pharmaceuticals has received approval from the European Union to broaden the label for its cystic fibrosis treatment.

Slater Sentinel
Mar 23rd, 2025
Stevens Capital Management LP Makes New $829,000 Investment in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Stevens Capital Management LP makes new $829,000 investment in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Investing.com
Mar 20th, 2025
BMO maintains Vertex stock Market Perform rating and $41 target

The reaffirmation of the rating and target came after Vertex held its first analyst day since its initial public offering in 2020.

Stat News
Mar 18th, 2025
Genetics expert is first NIH director to leave under Trump

He will be replaced on an interim basis by Director Ian Smith, a former Vertex Pharmaceuticals executive.